K
Kalaris Therapeutics, Inc. (KLRS)
NGM – Real vaqt narxi. Valyuta: USD
4.79
+0.06 (1.27%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
4.79
+0.06 (1.27%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Kalaris Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, keng tarqalgan ko'z to'r pardasi kasalliklarini davolashni ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya neovaskulyar yoshga bog'liq makula degeneratsiyasi (nAMD) ni davolash uchun klinik bosqichdagi endotelial o'sish omiliga (VEGF) qarshi bo'lgan TH103 ni ishlab chiqadi, bu esa 1b/2 bosqichida, shuningdek, boshqa ekssudativ va neovaskulyar ko'z to'r pardasi kasalliklarini davolash uchun mo'ljallangan. Kalaris Therapeutics, Inc. ilgari Theia Therapeutics, Inc. nomi bilan tanilgan va 2024-yil may oyida Kalaris Therapeutics, Inc. nomini o'zgartirgan. Kompaniya 2019-yilda tashkil etilgan va Nyu-Jersi shtatining Berkli-Hayts shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jill E. Porter Ph.D. | Senior Vice President of CMC |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer |
| Dr. Michael Philip Dybbs Ph.D. | Co-Founder & Director |
| Dr. Napoleone Ferrara M.D. | Independent Director & Co-Founder |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director & Co-Founder |
| Mr. Andrew Oxtoby | President, CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 8-K | d24879d8k.htm |
| 2026-04-24 | DEFA14A | d114103ddefa14a.htm |
| 2026-04-24 | ARS | d69530dars.pdf |
| 2026-04-10 | 8-K | d108368d8k.htm |
| 2026-04-03 | S-3 | d20326ds3.htm |
| 2026-03-17 | S-8 | d82569ds8.htm |
| 2026-03-09 | 8-K | d122695d8k.htm |
| 2025-12-18 | 8-K | d48530d8k.htm |
| 2025-12-17 | 8-K | d25416d8k.htm |
| 2025-11-12 | 8-K | d70447d8k.htm |
| Mr. Brett R. Hagen | Chief Accounting Officer and Principal Accounting & Financial Officer |
| Ms. Kristine Curtiss | Senior Vice President of Clinical |